vs

Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and SuperCom Ltd (SPCB). Click either name above to swap in a different company.

SuperCom Ltd is the larger business by last-quarter revenue ($14.2M vs $13.0M, roughly 1.1× Aquestive Therapeutics, Inc.). SuperCom Ltd runs the higher net margin — 37.5% vs -244.8%, a 282.3% gap on every dollar of revenue. On growth, Aquestive Therapeutics, Inc. posted the faster year-over-year revenue change (9.7% vs -1.5%). SuperCom Ltd produced more free cash flow last quarter ($-3.6M vs $-8.6M).

Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.

Super.com is a technology company headquartered in San Francisco and co-founded by Hussein Fazal and Henry Shi. The company provides financial services, including reward programs and travel bookings.

AQST vs SPCB — Head-to-Head

Bigger by revenue
SPCB
SPCB
1.1× larger
SPCB
$14.2M
$13.0M
AQST
Growing faster (revenue YoY)
AQST
AQST
+11.1% gap
AQST
9.7%
-1.5%
SPCB
Higher net margin
SPCB
SPCB
282.3% more per $
SPCB
37.5%
-244.8%
AQST
More free cash flow
SPCB
SPCB
$5.0M more FCF
SPCB
$-3.6M
$-8.6M
AQST

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
AQST
AQST
SPCB
SPCB
Revenue
$13.0M
$14.2M
Net Profit
$-31.9M
$5.3M
Gross Margin
55.2%
61.2%
Operating Margin
-221.6%
16.3%
Net Margin
-244.8%
37.5%
Revenue YoY
9.7%
-1.5%
Net Profit YoY
-86.8%
79.5%
EPS (diluted)
$-0.26
$1.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AQST
AQST
SPCB
SPCB
Q4 25
$13.0M
Q3 25
$12.8M
Q2 25
$10.0M
$14.2M
Q1 25
$8.7M
Q4 24
$11.9M
Q3 24
$13.5M
Q2 24
$20.1M
$14.4M
Q1 24
$12.1M
Net Profit
AQST
AQST
SPCB
SPCB
Q4 25
$-31.9M
Q3 25
$-15.4M
Q2 25
$-13.5M
$5.3M
Q1 25
$-22.9M
Q4 24
$-17.1M
Q3 24
$-11.5M
Q2 24
$-2.7M
$3.0M
Q1 24
$-12.8M
Gross Margin
AQST
AQST
SPCB
SPCB
Q4 25
55.2%
Q3 25
64.8%
Q2 25
54.4%
61.2%
Q1 25
58.1%
Q4 24
61.9%
Q3 24
67.2%
Q2 24
77.5%
52.3%
Q1 24
63.6%
Operating Margin
AQST
AQST
SPCB
SPCB
Q4 25
-221.6%
Q3 25
-89.6%
Q2 25
-113.6%
16.3%
Q1 25
-222.1%
Q4 24
-114.4%
Q3 24
-61.2%
Q2 24
0.3%
7.7%
Q1 24
-74.3%
Net Margin
AQST
AQST
SPCB
SPCB
Q4 25
-244.8%
Q3 25
-120.6%
Q2 25
-135.4%
37.5%
Q1 25
-263.0%
Q4 24
-143.7%
Q3 24
-85.0%
Q2 24
-13.7%
20.6%
Q1 24
-106.4%
EPS (diluted)
AQST
AQST
SPCB
SPCB
Q4 25
$-0.26
Q3 25
$-0.14
Q2 25
$-0.14
$1.32
Q1 25
$-0.24
Q4 24
$-0.18
Q3 24
$-0.13
Q2 24
$-0.03
$1.19
Q1 24
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AQST
AQST
SPCB
SPCB
Cash + ST InvestmentsLiquidity on hand
$15.0M
Total DebtLower is stronger
$27.5M
$23.6M
Stockholders' EquityBook value
$-33.7M
$37.3M
Total Assets
$160.4M
$65.5M
Debt / EquityLower = less leverage
0.63×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AQST
AQST
SPCB
SPCB
Q4 25
Q3 25
$129.1M
Q2 25
$60.5M
$15.0M
Q1 25
$68.7M
Q4 24
$71.5M
Q3 24
$77.9M
Q2 24
$89.9M
$5.7M
Q1 24
$95.2M
Total Debt
AQST
AQST
SPCB
SPCB
Q4 25
$27.5M
Q3 25
$45.0M
Q2 25
$45.0M
$23.6M
Q1 25
$45.0M
Q4 24
$32.5M
Q3 24
$45.0M
Q2 24
$45.0M
$29.2M
Q1 24
$45.0M
Stockholders' Equity
AQST
AQST
SPCB
SPCB
Q4 25
$-33.7M
Q3 25
$-4.1M
Q2 25
$-72.6M
$37.3M
Q1 25
$-60.9M
Q4 24
$-60.2M
Q3 24
$-45.4M
Q2 24
$-35.5M
$13.8M
Q1 24
$-36.3M
Total Assets
AQST
AQST
SPCB
SPCB
Q4 25
$160.4M
Q3 25
$163.6M
Q2 25
$93.7M
$65.5M
Q1 25
$102.2M
Q4 24
$101.4M
Q3 24
$110.0M
Q2 24
$117.6M
$49.6M
Q1 24
$129.5M
Debt / Equity
AQST
AQST
SPCB
SPCB
Q4 25
Q3 25
Q2 25
0.63×
Q1 25
Q4 24
Q3 24
Q2 24
2.11×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AQST
AQST
SPCB
SPCB
Operating Cash FlowLast quarter
$-8.5M
$-2.2M
Free Cash FlowOCF − Capex
$-8.6M
$-3.6M
FCF MarginFCF / Revenue
-65.7%
-25.3%
Capex IntensityCapex / Revenue
0.7%
10.0%
Cash ConversionOCF / Net Profit
-0.41×
TTM Free Cash FlowTrailing 4 quarters
$-53.0M
$-14.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AQST
AQST
SPCB
SPCB
Q4 25
$-8.5M
Q3 25
$-12.6M
Q2 25
$-7.9M
$-2.2M
Q1 25
$-23.4M
Q4 24
$-6.5M
Q3 24
$-11.9M
Q2 24
$-7.0M
$-950.0K
Q1 24
$-10.4M
Free Cash Flow
AQST
AQST
SPCB
SPCB
Q4 25
$-8.6M
Q3 25
$-12.9M
Q2 25
$-8.0M
$-3.6M
Q1 25
$-23.5M
Q4 24
$-6.5M
Q3 24
$-12.0M
Q2 24
$-7.0M
$-1.6M
Q1 24
$-10.4M
FCF Margin
AQST
AQST
SPCB
SPCB
Q4 25
-65.7%
Q3 25
-100.6%
Q2 25
-80.2%
-25.3%
Q1 25
-269.9%
Q4 24
-54.8%
Q3 24
-88.3%
Q2 24
-35.0%
-10.8%
Q1 24
-86.4%
Capex Intensity
AQST
AQST
SPCB
SPCB
Q4 25
0.7%
Q3 25
1.8%
Q2 25
1.1%
10.0%
Q1 25
1.5%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
0.2%
4.2%
Q1 24
0.2%
Cash Conversion
AQST
AQST
SPCB
SPCB
Q4 25
Q3 25
Q2 25
-0.41×
Q1 25
Q4 24
Q3 24
Q2 24
-0.32×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons